Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Coronary Sinus to Mitral Valve Annulus Topography and Response to the Percutaneous Coronary Sinus-Based Mitral Valve Contour System.

Rottländer D, Schneider T, Degen H, Laufenberg M, Chatrou M, Haude M.

EuroIntervention. 2019 Jul 2. pii: EIJ-D-19-00054. doi: 10.4244/EIJ-D-19-00054. [Epub ahead of print] No abstract available.

2.

Lesion preparation with cutting balloon angioplasty is associated with coronary aneurysm formation in polylactide bioresorbable vascular scaffold implantation.

Rottländer D, Schneider T, Degen H, Haude M.

EuroIntervention. 2017 Dec 8;13(12):e1483-e1486. doi: 10.4244/EIJ-D-17-00375. No abstract available.

3.

ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.

Degen H, Borst O, Ziegler M, Mojica Munoz AK, Jamasbi J, Walker B, Göbel S, Fassbender J, Adler K, Brandl R, Münch G, Lorenz R, Siess W, Gawaz M, Ungerer M.

J Am Heart Assoc. 2017 Jul 27;6(8). pii: e005991. doi: 10.1161/JAHA.117.005991.

4.

Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.

Mojica Muñoz AK, Jamasbi J, Uhland K, Degen H, Münch G, Ungerer M, Brandl R, Megens R, Weber C, Lorenz R, Siess W.

Thromb Haemost. 2017 Aug 1;117(8):1651-1659. doi: 10.1160/TH16-11-0856. Epub 2017 Jun 1.

PMID:
28569920
5.

A multicenter randomized trial comparing the effectiveness and safety of a novel vascular closure device to manual compression in anticoagulated patients undergoing percutaneous transfemoral procedures: The CELT ACD trial.

Wong SC, Laule M, Turi Z, Sanad W, Crowley J, Degen H, Bennett K, Coleman JE, Bergman G.

Catheter Cardiovasc Interv. 2017 Nov 1;90(5):756-765. doi: 10.1002/ccd.26991. Epub 2017 Mar 15.

PMID:
28296003
6.

The Carillon: strategies for optimal patient selection and optimised results.

Rottländer D, Degen H, Haude M.

EuroIntervention. 2016 Sep 18;12(Y):Y64-6. doi: 10.4244/EIJV12SYA16. Review. No abstract available.

7.

Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial.

Lipiecki J, Siminiak T, Sievert H, Müller-Ehmsen J, Degen H, Wu JC, Schandrin C, Kalmucki P, Hofmann I, Reuter D, Goldberg SL, Haude M.

Open Heart. 2016 Jul 8;3(2):e000411. doi: 10.1136/openhrt-2016-000411. eCollection 2016.

8.

Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.

Haude M, Erbel R, Erne P, Verheye S, Degen H, Vermeersch P, Weissman N, Prati F, Bruining N, Waksman R, Koolen J.

EuroIntervention. 2016 Jun 12;12(2):e160-6. doi: 10.4244/EIJ-D-15-00371.

9.

Deep inspiration breath hold in the prone position retracts the heart from the breast and internal mammary lymph node region.

Mulliez T, Van de Velde J, Veldeman L, De Gersem W, Vercauteren T, Speleers B, Degen H, Wouters J, Van Hoof T, van Greveling A, Monten C, Berwouts D, De Neve W.

Radiother Oncol. 2015 Dec;117(3):473-6. doi: 10.1016/j.radonc.2015.09.030. Epub 2015 Oct 8.

PMID:
26455452
10.

The balance of bleeding and ischaemic events in surgical patients after stenting.

Haude M, Degen H.

EuroIntervention. 2014 May;10(1):17-9. doi: 10.4244/EIJV10I1A3. No abstract available.

11.

Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment.

Waksman R, Prati F, Bruining N, Haude M, Böse D, Kitabata H, Erne P, Verheye S, Degen H, Vermeersch P, Di Vito L, Koolen J, Erbel R.

Circ Cardiovasc Interv. 2013 Dec;6(6):644-53. doi: 10.1161/CIRCINTERVENTIONS.113.000693. Epub 2013 Nov 19.

PMID:
24254708
12.

The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.

Goebel S, Li Z, Vogelmann J, Holthoff HP, Degen H, Hermann DM, Gawaz M, Ungerer M, Münch G.

PLoS One. 2013 Jul 23;8(7):e66960. doi: 10.1371/journal.pone.0066960. Print 2013.

13.

[Coronary sinus devices for treatment of functional mitral valve regurgitation. Solution or dead end?].

Degen H, Schneider T, Wilke J, Haude M.

Herz. 2013 Aug;38(5):490-500. doi: 10.1007/s00059-013-3866-3. Review. German.

PMID:
23836012
14.

Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.

Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J.

Lancet. 2013 Mar 9;381(9869):836-44.

PMID:
23332165
15.

Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-β1-adrenergic receptor antibody neutralization and of immune parameters.

Münch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truöl S, Degen H, Steiger N, Lohse MJ, Jahns R, Ungerer M.

Eur J Heart Fail. 2012 Nov;14(11):1230-9. doi: 10.1093/eurjhf/hfs118. Epub 2012 Sep 11. Erratum in: Eur J Heart Fail. 2013 Apr;15(4):478. Dosage error in article text.

16.

The recombinant bifunctional protein αCD133-GPVI promotes repair of the infarcted myocardium in mice.

Baumer Y, Leder C, Ziegler M, Schönberger T, Ochmann C, Perk A, Degen H, Schmid-Horch B, Elvers M, Münch G, Ungerer M, Schlosshauer B, Gawaz M.

J Thromb Haemost. 2012 Jun;10(6):1152-64. doi: 10.1111/j.1538-7836.2012.04710.x.

17.

Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis.

Kleinbongard P, Böse D, Konorza T, Steinhilber F, Möhlenkamp S, Eggebrecht H, Baars T, Degen H, Haude M, Levkau B, Erbel R, Heusch G.

Basic Res Cardiol. 2011 Jun;106(4):681-9. doi: 10.1007/s00395-011-0177-9. Epub 2011 Apr 7.

PMID:
21472462
18.

Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation.

Kleinbongard P, Böse D, Baars T, Möhlenkamp S, Konorza T, Schöner S, Elter-Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R, Heusch G.

Circ Res. 2011 Feb 4;108(3):344-52. doi: 10.1161/CIRCRESAHA.110.235713. Epub 2010 Dec 23.

PMID:
21183739
19.

[Management of a catheter-induced rupture of a pulmonary artery].

Damm C, Degen H, Stoepel C, Haude M.

Dtsch Med Wochenschr. 2010 Oct;135(39):1914-7. doi: 10.1055/s-0030-1263338. Epub 2010 Sep 21. German.

PMID:
20859841
20.

Femoral artery puncture.

Haude M, Degen H, Schillings C, Stoepel C.

EuroIntervention. 2010 Jan;5(6):751. No abstract available.

PMID:
20142229
21.
22.

Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study.

Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tübler T, Degen H, Brandt MC, Van Bibber R, Goldberg S, Reuter DG, Hoppe UC.

Circulation. 2009 Jul 28;120(4):326-33. doi: 10.1161/CIRCULATIONAHA.109.849885. Epub 2009 Jul 13.

23.

Percutaneous mitral annuloplasty device leaves free access to cardiac veins for resynchronization therapy.

Hoppe UC, Brandt MC, Degen H, Dodos F, Schneider T, Stoepel C, Kroener A, Haude M.

Catheter Cardiovasc Interv. 2009 Sep 1;74(3):506-11. doi: 10.1002/ccd.22097.

PMID:
19472350
24.

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.

Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horváth Z, Kéri G, Müller S, Cotten M, Ullrich A, Daub H.

Cancer Res. 2005 Aug 1;65(15):6919-26.

25.

Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay.

Mett H, Hölscher K, Degen H, Esdar C, De Neumann BF, Flicke B, Freudenreich T, Holzer G, Schinzel S, Stamminger T, Stein-Gerlach M, Marschall M, Herget T.

J Biomol Screen. 2005 Feb;10(1):36-45.

PMID:
15695342
26.

[Guideline conforming interventional therapy of acute ST elevation infarct in rural regions by network development--on the contribution in DMW 42/2004].

Degen H.

Dtsch Med Wochenschr. 2005 Feb 11;130(6):299; author reply 300. German. No abstract available.

PMID:
15692909
27.

Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation.

Kirchhof P, Degen H, Franz MR, Eckardt L, Fabritz L, Milberg P, Läer S, Neumann J, Breithardt G, Haverkamp W.

J Pharmacol Exp Ther. 2003 Apr;305(1):257-63.

PMID:
12649377
28.

Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.

Knollmann BC, Kirchhof P, Sirenko SG, Degen H, Greene AE, Schober T, Mackow JC, Fabritz L, Potter JD, Morad M.

Circ Res. 2003 Mar 7;92(4):428-36. Epub 2003 Feb 6.

PMID:
12600890
30.

Asymmetric Weitz-Scheffer epoxidation of isoflavones with hydroperoxides mediated by optically active phase-transfer catalysts.

Adam W, Rao PB, Degen HG, Levai A, Patonay T, Saha-Möller CR.

J Org Chem. 2002 Jan 11;67(1):259-64.

PMID:
11777469
31.

U-373 MG glioblastoma and IMR-32 neuroblastoma cell lines express the dopamine and vesicular monoamine transporters.

Koutsilieri E, Kornhuber J, Degen HJ, Lesch KP, Sopper S, ter Meulen V, Riederer P.

J Neurosci Res. 1996 Aug 1;45(3):269-75.

PMID:
8841987
33.
34.
35.

Drug-using and nonusing women: potential for child abuse, child-rearing attitudes, social support, and affection for expected baby.

Williams-Petersen MG, Myers BJ, Degen HM, Knisely JS, Elswick RK Jr, Schnoll SS.

Int J Addict. 1994 Oct;29(12):1631-43.

PMID:
7836024
37.

[Genetic aspects of symptomatic epilepsy based on waking and sleep EEG recordings in siblings].

Degen R, Degen HE.

Nervenarzt. 1993 Aug;64(8):504-10. German.

PMID:
8413748
38.

Social support and anxiety in pregnant drug abusers and nonusers: unexpected findings of few differences.

Degen HM, Myers BJ, Williams-Petersen MG, Knisely JS, Schnoll SS.

Drug Alcohol Depend. 1993 Mar;32(1):37-44.

PMID:
8486083
39.

On the genetics of complex partial seizures: waking and sleep EEGs in siblings.

Degen R, Degen HE, Köneke B.

J Neurol. 1993;240(3):151-5.

PMID:
8482987
41.
42.

A contribution to the genetics of febrile seizures: waking and sleep EEG in siblings.

Degen R, Degen HE, Hans K.

Epilepsia. 1991 Jul-Aug;32(4):515-22.

PMID:
1868809
43.

Regulation of histone H5 and H1 zero gene expression under the control of vaccinia virus-specific sequences in interferon-treated chick embryo fibroblasts.

Grün J, Redmann-Müller I, Blum D, Degen HJ, Doenecke D, Zentgraf HW, Jungwirth C.

Virology. 1991 Feb;180(2):535-42.

PMID:
1703369
44.

[Animal transport and animal welfare].

Degen H.

Dtsch Tierarztl Wochenschr. 1991 Jan;98(1):24-6. German. No abstract available.

PMID:
2040219
45.

Sleep and sleep deprivation in epileptology.

Degen R, Degen HE.

Epilepsy Res Suppl. 1991;2:235-60. No abstract available.

PMID:
1760093
46.

Some genetic aspects of rolandic epilepsy: waking and sleep EEGs in siblings.

Degen R, Degen HE.

Epilepsia. 1990 Nov-Dec;31(6):795-801.

PMID:
2123156
47.
48.

Two interferon sensitive steps in the replication cycle of Rous sarcoma virus.

Zens W, Degen HJ, Barnekow A, Gelderblom H, Jungwirth C.

Virology. 1989 Aug;171(2):535-42.

PMID:
2474893
49.

[Animal welfare requirements for the raising and breeding of pheasants].

Degen H.

Dtsch Tierarztl Wochenschr. 1989 Mar;96(3):123-4. German.

PMID:
2651074
50.

[Pig racing from the animal welfare view].

Degen H.

Dtsch Tierarztl Wochenschr. 1988 Feb;95(2):81-3. German. No abstract available.

PMID:
3286209

Supplemental Content

Support Center